Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

1.

HSP90 inhibitors as therapy for multiple myeloma.

Usmani SZ, Chiosis G.

Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S77-81. doi: 10.1016/j.clml.2011.03.027. Epub 2011 Apr 28. Review.

PMID:
22035754
[PubMed - indexed for MEDLINE]
2.

17 AAG for HSP90 inhibition in cancer--from bench to bedside.

Usmani SZ, Bona R, Li Z.

Curr Mol Med. 2009 Jun;9(5):654-64. Review.

PMID:
19601813
[PubMed - indexed for MEDLINE]
3.

Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.

Khong T, Spencer A.

Mol Cancer Ther. 2011 Oct;10(10):1909-17. doi: 10.1158/1535-7163.MCT-11-0174. Epub 2011 Aug 22.

PMID:
21859842
[PubMed - indexed for MEDLINE]
Free Article
4.

Heat shock proteins as targets in oncology.

Giménez Ortiz A, Montalar Salcedo J.

Clin Transl Oncol. 2010 Mar;12(3):166-73. doi: 10.1007/s12094-010-0486-8. Review.

PMID:
20231121
[PubMed - indexed for MEDLINE]
5.

Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors.

Allegra A, Sant'antonio E, Penna G, Alonci A, D'Angelo A, Russo S, Cannavò A, Gerace D, Musolino C.

Eur J Haematol. 2011 Feb;86(2):93-110. doi: 10.1111/j.1600-0609.2010.01558.x. Epub 2010 Dec 20. Review.

PMID:
21114539
[PubMed - indexed for MEDLINE]
6.

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.

Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC.

Br J Haematol. 2011 Feb;152(4):367-79. doi: 10.1111/j.1365-2141.2010.08360.x. Epub 2011 Jan 10. Review.

PMID:
21219297
[PubMed - indexed for MEDLINE]
7.

Hsp90 inhibitors as promising agents for radiotherapy.

Kabakov AE, Kudryavtsev VA, Gabai VL.

J Mol Med (Berl). 2010 Mar;88(3):241-7. doi: 10.1007/s00109-009-0562-0. Epub 2009 Nov 28. Review.

PMID:
19946660
[PubMed - indexed for MEDLINE]
8.

Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.

Reikvam H, Ersvaer E, Bruserud O.

Curr Cancer Drug Targets. 2009 Sep;9(6):761-76. Review.

PMID:
19754360
[PubMed - indexed for MEDLINE]
9.

Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800.

Stühmer T, Chatterjee M, Grella E, Seggewiss R, Langer C, Müller S, Schoepfer J, Garcia-Echeverria C, Quadt C, Jensen MR, Einsele H, Bargou RC.

Br J Haematol. 2009 Nov;147(3):319-27. doi: 10.1111/j.1365-2141.2009.07852.x. Epub 2009 Aug 13.

PMID:
19686236
[PubMed - indexed for MEDLINE]
10.

Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90.

Zhao M, Ma J, Zhu HY, Zhang XH, Du ZY, Xu YJ, Yu XD.

Mol Cancer. 2011 Aug 29;10:104. doi: 10.1186/1476-4598-10-104.

PMID:
21871133
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.

Stravopodis DJ, Margaritis LH, Voutsinas GE.

Curr Med Chem. 2007;14(29):3122-38. Review.

PMID:
18220746
[PubMed - indexed for MEDLINE]
12.

New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.

Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y, Akinaga S, Soga S, Shiotsu Y.

Clin Cancer Res. 2010 May 15;16(10):2792-802. doi: 10.1158/1078-0432.CCR-09-3112. Epub 2010 Apr 20.

PMID:
20406843
[PubMed - indexed for MEDLINE]
Free Article
13.

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.

Powers MV, Workman P.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35. Review.

PMID:
17259553
[PubMed - indexed for MEDLINE]
Free Article
14.

IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells.

Patterson J, Palombella VJ, Fritz C, Normant E.

Cancer Chemother Pharmacol. 2008 May;61(6):923-32. Epub 2007 Jul 12.

PMID:
17624530
[PubMed - indexed for MEDLINE]
15.

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.

Kaiser M, Lamottke B, Mieth M, Jensen MR, Quadt C, Garcia-Echeverria C, Atadja P, Heider U, von Metzler I, Türkmen S, Sezer O.

Eur J Haematol. 2010 Apr;84(4):337-44. doi: 10.1111/j.1600-0609.2009.01403.x. Epub 2009 Dec 17.

PMID:
20028416
[PubMed - indexed for MEDLINE]
16.

[Molecular chaperone HSP90 as a novel target for cancer chemotherapy].

Miyata Y.

Nihon Yakurigaku Zasshi. 2003 Jan;121(1):33-42. Review. Japanese.

PMID:
12617036
[PubMed - indexed for MEDLINE]
17.

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.

Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.

Clin Cancer Res. 2006 Nov 15;12(22):6826-35.

PMID:
17121904
[PubMed - indexed for MEDLINE]
Free Article
18.

Heat shock protein 90: a unique chemotherapeutic target.

Cullinan SB, Whitesell L.

Semin Oncol. 2006 Aug;33(4):457-65. Review.

PMID:
16890800
[PubMed - indexed for MEDLINE]
19.

Targeting multiple signal transduction pathways through inhibition of Hsp90.

Zhang H, Burrows F.

J Mol Med (Berl). 2004 Aug;82(8):488-99. Epub 2004 May 27. Review.

PMID:
15168026
[PubMed - indexed for MEDLINE]
20.

Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells.

Ge F, Lu XP, Zeng HL, He QY, Xiong S, Jin L, He QY.

J Proteome Res. 2009 Jun;8(6):3006-19. doi: 10.1021/pr9001004.

PMID:
19364129
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk